1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)
    Meeting Abstract

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma
    Meeting Abstract

    Atkins, M. B.; Kirkwood, J. M.; Wolchok, J. D.; Callahan, M. K.; Kluger, H. M.; Postow, M. A.; Segal, N. H.; Lesokhin, A. M.; Balogh, A.; Re, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial
    Meeting Abstract

    Armstrong, D. K.; Moore, K. N.; Miller, A.; Bell-McGuinn, K. M.; Schilder, R. J.; Fracasso, P. M.; Walker, J. L.; Duska, L. R.; Mathews, C. A.; Chen, A. P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Response to A+CHP by CD30 expression in the ECHELON-2 trial
    Meeting Abstract

    Advani, R. H.; Horwitz, S. M.; Iyer, S. P.; Bartlett, N. L.; Kim, W. S.; Tilly, H.; Belada, D.; Feldman, T.; Illés, A.; Jacobsen, E. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R.; Zhu, A.; Ngai, D.; McGee, E.; Chintala, N.; Messinger, J.; Cheema, W.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Arnason, J. E.; Lunning, M. A.; Solomon, S. R.; Farazi, T.; Garcia, J.; Xie, B.; Newhall, K. J.; Dehner, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Patient (pt) experiences with avelumab in treatment-naive metastatic Merkel cell carcinoma (mMCC): Qualitative interview findings from a registrational clinical trial
    Meeting Abstract

    Bharmal, M.; Lambert, J.; Russell, J. S.; Lebbé, C.; Chmielowski, B.; Hennessy, M.; Marrel, A.; D'Angelo, S. P.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial)
    Meeting Abstract

    Diab, A.; Marcondes, M.; Kotzin, B.; Tagliaferri, M. A.; Hoch, U.; Li, Y.; Cattaruzza, F.; Zalevsky, J.; Brohl, A. S.; Brugarolas, J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Meeting Abstract

    Shah, A. Y.; Kotecha, R.; Lemke, E.; Chandramohan, A.; Chaim, J.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa)
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Knezevic, A.; Bambury, R. M.; Hatzoglou, V.; Autio, K. A.; Abida, W.; Gopalan, A.; Fine, S.; Danila, D. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save